What drives this drug packaging business?
West Pharmaceutical Services makes packaging and delivery components used in injectable drug administration. The business is tied to primary containment and related systems that help store and deliver medicines. It sells into life sciences and pharmaceutical workflows where consistency and quality control matter. The company’s equity value sits around USD 23.3 billion.
Are reinvestment levels supporting growth?
FundamentalsFor 2025, reported in USD, revenue reached about USD 3.07 billion, rising 6.3% year over year, alongside net income of roughly USD 601 million. Over the trailing period, gross margin was 36.28%, operating margin 20.34%, and net margin 16.85%.
Reinvestment remained visible in cash uses: depreciation and amortization totaled about USD 169 million, while capital spending was higher at roughly USD 286 million. The balance sheet held around USD 791 million of cash against USD 203 million of total debt.
Is the market overpaying for stability?
DCF / MultiplesAt USD 362.44, the stock trades well above the range implied by the discounted cash flow model. The headline multiples reinforce that setup, with a 46.06 P/E, 29.77 EV/EBITDA, and 7.76 price-to-sales ratio.
Valuation leaves little room for error
TakeawayThe price assumes reinvestment keeps translating into durable earnings power. That requires growth to stay healthy while margins hold up. If spending rises faster than revenue, returns can compress. On this setup, the valuation leaves little tolerance for stumbles.